Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations

TL;DR

This review discusses how proteomics can help identify biomarkers for diagnosing and treating idiopathic pulmonary fibrosis, a deadly lung disease.

Contribution

The paper highlights recent proteomic advancements and their potential for improving IPF diagnosis and therapy.

Findings

Proteomics has identified key molecular pathways involved in IPF progression.

Recent mass spectrometry advancements offer new opportunities for biomarker discovery.

Proteomic biomarkers may aid in predicting therapy response and disease progression.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, rare, and fatal disease that is the consequence of aberrant remodeling and defective repair mechanisms within the lung, culminating in the loss of alveolar integrity. Although significant progress has been made in understanding the pathogenesis, it would be crucial to identify biomarkers for diagnosis, prognosis, and prediction of therapy response to improve the management of this challenging and debilitating disease. Omics technologies have profoundly advanced the understanding of disease mechanisms, presenting considerable potential for the identification of clinically relevant biomarkers. To date, specific molecular pathways have been implicated in the onset and progression of idiopathic pulmonary fibrosis, including abnormal wounding, fibroblast proliferation, inflammation, deposition of the extracellular matrix, oxidative stress, endoplasmic reticulum stress, and the coagulation system. This review highlights the role of proteomics in identifying key biomarkers for IPF, focusing on their clinical relevance, including diagnosis, prognosis, disease progression, and the identification of new therapeutic options, in light of the most recent technological advancements in mass spectrometry.

Figures